Ovarian granulosa cell tumour – Diagnostics – Overview of Information and Clinical Research

Ovarian granulosa cell tumour is a rare type of ovarian cancer that often produces hormones, leading to unusual symptoms like irregular bleeding or early puberty in young girls. While these tumours are uncommon, representing about 5% of ovarian cancers, most are found early when treatment outcomes are typically favorable. Understanding when and how to seek proper diagnosis can make a significant difference in managing this condition effectively.

Introduction: Who Should Seek Diagnostics

If you notice certain warning signs, it may be time to consult a healthcare provider about possible ovarian granulosa cell tumour. Women who experience abnormal bleeding patterns should pay particular attention. This includes irregular periods, unusually heavy menstrual bleeding, or any vaginal bleeding that occurs after menopause has already begun. These symptoms happen because granulosa cell tumours frequently produce excess amounts of estrogen, which is a female sex hormone that affects the reproductive system.^[1]

Young girls and their parents should be alert to signs of early puberty, which could indicate a hormone-producing tumour. If a girl begins developing adult physical characteristics at an unexpectedly young age, this warrants medical evaluation. In adult women, other concerning symptoms include a noticeable increase in abdomen size, sometimes described as a swollen belly, along with persistent abdominal or pelvic pain. Some women also notice breast tenderness or soreness that seems unrelated to their menstrual cycle.^[1]

The average age when these tumours are diagnosed is around 50 years old, though they can appear at any age. About 95% of diagnoses occur in mature adult women, while the remaining 5% are found in younger individuals under 30 years old, typically as the juvenile type of granulosa cell tumour. Because these tumours often cause symptoms related to hormone production, many women seek medical attention relatively early, which contributes to better treatment outcomes.^[1]^[2]

⚠️ Important

Without proper treatment, granulosa cell tumours can lead to serious health complications. The excess estrogen produced by these tumours may cause the lining of the uterus to become abnormally thick, a condition called endometrial hyperplasia. This increases the risk of developing uterine cancer or breast cancer. The tumours can also lead to infertility problems. These potential complications make early diagnosis and treatment particularly important.^[1]

Women should also be aware that symptoms might include constipation, needing to urinate more frequently than usual, or a noticeable lump in the abdomen or pelvis area. While abdominal pain is possible, it is usually only experienced if the tumour ruptures or bursts, which is a less common occurrence. Any combination of these symptoms, especially when they persist and do not resolve on their own, should prompt a visit to a healthcare provider for proper evaluation.^[1]^[5]

Diagnostic Methods for Identifying Granulosa Cell Tumours

Healthcare providers rely on several different approaches to diagnose ovarian granulosa cell tumours and distinguish them from other types of ovarian conditions. The diagnostic process typically begins with imaging techniques, which allow doctors to see inside the body without surgery. These visual examinations help identify the presence, size, and location of any tumours in the ovaries.^[1]

Imaging Techniques

A transvaginal ultrasound is often one of the first imaging tests performed when ovarian abnormalities are suspected. During this procedure, a small probe is inserted into the vagina to create detailed images of the ovaries using sound waves. This type of ultrasound provides clearer pictures of the ovaries compared to an external abdominal ultrasound because the probe is closer to the organs being examined. Pelvic ultrasound can reveal the size and characteristics of any masses present on the ovaries.^[1]^[5]

For a more detailed view, doctors may order a CT scan, which stands for computed tomography. This imaging test uses X-rays taken from multiple angles and combines them with computer processing to create cross-sectional images of the body. CT scans are particularly useful for determining whether a tumour has spread beyond the ovaries to other areas of the abdomen or pelvis. They provide more comprehensive information than ultrasound alone.^[1]^[5]

MRI, or magnetic resonance imaging, is another imaging option that uses powerful magnets and radio waves instead of radiation to create detailed pictures of soft tissues. MRI scans can provide exceptional detail about the structure of ovarian tumours and surrounding tissues. Some doctors also use chest X-rays to check whether the cancer has spread to the lungs, and PET scans may be employed in certain cases to detect cancer activity throughout the body.^[5]

Blood Tests and Tumour Markers

Blood tests play a crucial role in diagnosing granulosa cell tumours because these tumours often produce measurable substances called tumour markers. The most important marker for granulosa cell tumours is inhibin, a hormone that these tumours produce in elevated amounts. When doctors measure inhibin levels in the blood and find them significantly elevated, this strongly suggests the presence of a granulosa cell tumour. Testing for inhibin can also help doctors monitor the effectiveness of treatment and watch for cancer recurrence after treatment is completed.^[1]^[5]

Other blood tests may include checking levels of CA125 and anti-Müllerian hormone (AMH). While these markers are not specific only to granulosa cell tumours, they can provide additional information that helps doctors make a diagnosis. Healthcare providers may also order blood tests to rule out other conditions that could cause similar symptoms. The combination of imaging findings and blood marker results helps doctors distinguish granulosa cell tumours from other types of ovarian cancer and from non-cancerous ovarian conditions.^[5]

Tissue Examination and Staging

The definitive way to confirm a granulosa cell tumour diagnosis is through examination of tissue samples. This usually happens during surgery, when the tumour is removed and sent to a laboratory for analysis. A specialist called a pathologist examines the tissue under a microscope to identify the specific type of cells and confirm whether it is indeed a granulosa cell tumour. The pathologist can distinguish between adult-type and juvenile-type granulosa cell tumours based on how the cells look.^[2]^[3]

During surgery, doctors also perform a process called staging, which determines how far the cancer has spread. Stage 1 means the cancer is contained only within the ovary or ovaries. Stage 2 indicates the cancer has spread to nearby structures within the pelvis, such as the fallopian tubes or uterus. Stage 3 means the cancer has reached the lymph nodes or the membrane lining the abdomen, called the peritoneum. Stage 4 is when cancer has spread to distant organs like the lungs or liver. Most granulosa cell tumours are found at stage 1, which is one reason why outcomes are generally good.^[1]^[5]

Genetic Testing

Scientists have discovered that most adult-type granulosa cell tumours contain a specific genetic change. Approximately 97% of these tumours have a mutation, or alteration, in a gene called FOXL2. This particular mutation involves a specific change in the DNA sequence of the gene. While this mutation is found in nearly all adult granulosa cell tumours, it is not typically used as a routine diagnostic test because imaging and blood markers usually provide sufficient information. However, the discovery of this mutation has been important for understanding what causes these tumours to develop.^[3]^[7]

Juvenile granulosa cell tumours have different genetic characteristics. Research has shown that more than 60% of juvenile tumours have changes in a gene for an enzyme called AKT1. These genetic findings help scientists understand why juvenile and adult types behave somewhat differently and may eventually lead to new targeted treatments.^[3]

Diagnostics Used for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or approaches to managing granulosa cell tumours. When researchers design these trials, they establish specific criteria that patients must meet to participate. The diagnostic tests used to determine whether someone qualifies for a clinical trial are similar to those used for standard diagnosis, but they are applied with particular attention to details that matter for the study.^[11]

For enrollment in clinical trials studying recurrent granulosa cell tumours, researchers typically require confirmation that the tumour has returned after initial treatment. This confirmation usually involves imaging tests such as CT scans or MRI to identify and measure tumour masses. The size and number of measurable tumours often determine whether someone is eligible, as researchers need to be able to track whether the experimental treatment causes tumours to shrink.^[11]

Blood tests for tumour markers, particularly inhibin levels, are frequently required for clinical trial enrollment. Elevated inhibin levels can confirm that a patient has active granulosa cell tumour tissue, even when imaging might not show clear masses. Some trials may also require documentation of the tumour’s stage and grade from the original diagnosis. The grade refers to how abnormal the cells look under a microscope, with higher grades indicating faster-growing tumours.^[5]

⚠️ Important

Clinical trials may have strict requirements about previous treatments. For instance, a trial might only accept patients who have received certain types of chemotherapy or who have never received chemotherapy at all. Complete medical records, including pathology reports from previous surgeries and documentation of all prior treatments, are essential for determining trial eligibility. This careful selection helps researchers ensure their study results are reliable and meaningful.^[11]

Some clinical trials studying systemic therapies like chemotherapy or targeted drugs require assessment of overall health status through various blood tests. These might include tests of kidney function, liver function, and blood cell counts to ensure patients are healthy enough to tolerate the experimental treatment safely. Baseline imaging is typically performed before starting any trial treatment so that doctors can later compare new images to see if the treatment is working.^[12]

For trials examining anti-hormonal therapies for granulosa cell tumours, researchers may want to verify that tumours produce hormones by checking estrogen levels or confirming the presence of hormone receptors in tumour tissue. Since granulosa cell tumours are known as “functioning tumours” because they produce estrogen, this characteristic may be important for certain experimental treatments. The staging system used for clinical trials is the same as that used in regular clinical practice, typically following the FIGO staging system for ovarian cancers.^[5]^[12]

Prognosis and Survival Rate

Prognosis

The outlook for patients with ovarian granulosa cell tumours depends largely on the stage at which the cancer is discovered. Most women are diagnosed when the tumour is still confined to the ovary, which is stage 1 disease. Somewhere between 78% and 91% of patients are diagnosed at this early stage. When granulosa cell tumours are caught early, before they have spread beyond the ovaries, the prognosis is usually very good. These tumours generally grow slowly compared to other types of ovarian cancer, which contributes to better overall outcomes.^[6]^[16]

The stage of disease is considered the most important factor affecting prognosis. Advanced stage disease, meaning cancer that has spread beyond the ovaries to other parts of the abdomen or to distant organs, is associated with poorer outcomes. Another important consideration is whether any cancer remains after surgery. Patients who have residual disease after their operation tend to have less favorable outcomes than those in whom all visible tumour was successfully removed.^[9]^[16]

One unique characteristic of granulosa cell tumours is their tendency toward late recurrence. Unlike many cancers that recur within the first few years after treatment, granulosa cell tumours can come back even decades later. Some patients experience recurrence after 30 years or more. This pattern of late recurrence means that patients need lifelong follow-up care, even when they have been cancer-free for many years. The juvenile type of granulosa cell tumour can be more aggressive if it has already spread outside the ovary at diagnosis and may be somewhat more likely to recur within a few years compared to the adult type.^[1]^[2]^[5]

Survival Rate

Survival statistics for ovarian granulosa cell tumours are generally encouraging, particularly for early-stage disease. Studies have shown that the estimated 5-year overall survival rate ranges from approximately 84% to 95% for patients with early-stage tumours. This means that about 84 to 95 out of every 100 patients with early-stage disease are still alive five years after diagnosis. The 10-year survival rate remains favorable as well, with studies reporting rates between 72% and 84% to 95%, depending on the stage at diagnosis.^[9]^[16]

When looking at event-free survival, which measures how long patients remain without cancer recurrence or progression, the numbers show that approximately 76% of patients are event-free at 5 years, and about 53% remain event-free at 10 years. These statistics reflect the characteristic pattern of granulosa cell tumours to recur later in some patients. Despite the possibility of late recurrence, many patients can be successfully treated again if the cancer returns.^[9]^[16]

Advanced stage disease carries a more serious prognosis. While specific survival numbers vary between studies, patients whose cancer has spread beyond the ovaries at the time of diagnosis have notably lower survival rates compared to early-stage patients. However, even with advanced disease, granulosa cell tumours tend to grow more slowly than other ovarian cancers, which may provide more time for treatment interventions. The relatively favorable overall prognosis compared to other types of ovarian cancer is one of the distinctive features of granulosa cell tumours.^[16]

#1 Clinical Trials Search in Europe